Breaking News
Get 40% Off 0
🔎 See NVDA's full ProTips for an instant risks or rewards Claim 40% OFF

1 Stock to Buy, 1 Stock to Sell This Week: Lululemon, Pfizer

By Investing.com (Jesse Cohen)Stock MarketsOct 15, 2023 05:10AM ET
www.investing.com/analysis/1-stock-to-buy-1-stock-to-sell-this-week-lululemon-pfizer-200642706
1 Stock to Buy, 1 Stock to Sell This Week: Lululemon, Pfizer
By Investing.com (Jesse Cohen)   |  Oct 15, 2023 05:10AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
PFE
+0.29%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LULU
-0.26%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
  • Retail sales data, Q3 earnings season barrage, geopolitical fears in focus.
  • Lululemon is a buy on news it will be joining the S&P 500.
  • Pfizer is set to underperform after providing shock guidance cut.
  • Looking for more actionable trade ideas to navigate the current market volatility? Members of InvestingPro get exclusive ideas and guidance to navigate any climate. Learn More »

Stocks on Wall Street ended mostly lower on Friday to wrap up a volatile week, as a spike in oil prices and rising inflation expectations soured investors on riskier bets.

Despite Friday’s weak performance, the blue-chip Dow Jones Industrial Average rose 0.8% on the week, the benchmark S&P 500 tacked on 0.4%, while the tech-heavy Nasdaq Composite dipped 0.2%.

S&P 500 vs. Nasdaq vs. Dow
S&P 500 vs. Nasdaq vs. Dow

The week ahead is expected to be another busy one as investors continue to assess the outlook for the economy, inflation, interest rates and corporate earnings.

Most important on the economic calendar will be Tuesday’s U.S. retail sales report for September, with economists estimating a headline increase of 0.2% after sales rose 0.6% during the prior month.

Investors will also scrutinize a speech from Fed Chair Jerome Powell on Thursday for clues on the outlook for interest rates. As of Sunday morning, financial markets see a 94% chance of the Fed holding rates at current levels at its November meeting, according to Investing.com’s Fed Rate Monitor Tool.

Economic Calendar
Economic Calendar

Meanwhile, third quarter earnings season shifts into high gear, with Tesla (NASDAQ:TSLA) and Netflix (NASDAQ:NFLX) leading the charge. Other high-profile companies reporting include Bank of America (NYSE:BAC), Goldman Sachs (NYSE:GS), Morgan Stanley (NYSE:MS), American Express (NYSE:AXP), Johnson & Johnson (NYSE:JNJ), Procter & Gamble (NYSE:PG), AT&T (NYSE:T), American Airlines (NASDAQ:AAL), United Airlines (NASDAQ:UAL), and Taiwan Semiconductor (NYSE:TSM).

In addition to earnings, investors will also monitor news out of the Middle East amid growing fears that the Israel-Hamas war could escalate geopolitical tensions in the region.

Regardless of which direction the market goes next week, below I highlight one stock likely to be in demand and another which could see fresh downside.

Remember though, my timeframe is just for the week ahead, Monday, October 16 - Friday, October 20.

Stock To Buy: Lululemon

I believe Lululemon's (NASDAQ:LULU) stock will outperform in the week ahead, after it was announced that shares of the yoga wear retailer will be added to the benchmark S&P 500 index.

S&P Dow Jones Indices said late Friday that the Vancouver-based athletic apparel maker will join the widely followed index - which tracks the stock performance of 500 of the largest companies listed on the U.S. stock market - before the start of trading on Wednesday, October 18.

Lululemon is replacing video-game company Activision Blizzard (NASDAQ:ATVI), whose $69 billion acquisition by Microsoft (NASDAQ:MSFT) was completed on Friday after clearing numerous regulatory hurdles.

History has shown that stocks often enjoy a boost after the announcement of their addition to the S&P 500. In general, stocks making the jump usually benefit from increased liquidity and greater interest from individual and institutional investors, two factors that can potentially propel a company’s share price higher.

Indeed, past studies have found that companies added to the S&P 500 experience increases in their stock price as passive investment funds that are benchmarked to the index are forced to buy shares in order to realign with the S&P 500’s new composition.

Lululemon Chart
Lululemon Chart

LULU stock ended Friday’s session at $377.69, not far from a 52-week high of $406.75 touched on September 1. At current levels, Lululemon has a market cap of around $48 billion, making it one of the most valuable exercise apparel companies in the world.

Shares are up 17.9% year-to-date, much better than the 3% decline recorded by the SPDR® S&P Retail ETF (NYSE:XRT), which tracks a broad-based, equal-weighted index of U.S. retail companies in the S&P 500.

It should be noted that Lululemon’s stock remains extremely undervalued according to the quantitative models in InvestingPro, and could see an increase of about 18% from Friday’s closing price to its ‘Fair Value’ target of roughly $446.

Lululemon Fair Value
Lululemon Fair Value

Despite a difficult environment for retailers, investors have turned more bullish on the sportswear brand as it benefits from favorable consumer demand trends and an improving fundamental outlook. Lululemon has beaten Wall Street’s profit expectations for 13 consecutive quarters, a testament to the strength of its underlying business, its loyal customer base, as well as strong execution across the company.

Stock To Sell: Pfizer

I believe Pfizer's (NYSE:PFE) stock will suffer a challenging week ahead, with a potential drop to new 52-week lows on the horizon, as investors react to fresh negative developments plaguing one of the world’s largest pharmaceutical companies.

Pfizer on Friday cut its full-year revenue forecast by $9 billion due to lower-than-expected sales of its COVID-19 vaccine and treatment. The company foresees a $7 billion reduction in expected revenue for its Paxlovid antiviral Covid treatment pill, and a $2 billion decline in revenue for its Comirnaty Covid vaccine it makes with BioNTech (NASDAQ:BNTX).

As a result, Pfizer’s management now expects 2023 revenue to be in the range of $58 billion to $61 billion, down sharply from its prior forecast of $67 billion to $70 billion.

Pfizer executives, including CEO Albert Bourla, will hold a conference call with investors on Monday at 8:00AM EST to discuss the new outlook.

The pharmaceutical giant also warned that it will take a one-time cash charge of $3 billion, related to severance, among other things, as it implements fresh cost-cutting measures.

Pfizer Chart
Pfizer Chart

PFE stock - which fell to a more than two-year low of $31.77 on September 28 - ended at $32.12 on Friday. At current levels, the New York-based drugmaker has a market cap of $181.3 billion.

Shares have underperformed the broader market by a wide margin in 2023, tumbling 37.3% year-to-date, amid a significant slowdown in sales of its Covid-related product portfolio.

Underscoring several headwinds Pfizer faces amid the current backdrop, an InvestingPro survey of analyst earnings revisions points to mounting pessimism ahead of the company’s Q3 update on October 31, with 14 out of 15 analysts slashing their EPS estimates.

Pfizer EPS Revisions
Pfizer EPS Revisions

With InvestingPro, you can conveniently access a single-page view of complete and comprehensive information about different companies all in one place, eliminating the need to gather data from multiple sources and saving you time and effort.

Disclosure: At the time of writing, I am long on the Dow Jones Industrial Average, the S&P 500, and the Nasdaq 100 via the SPDR Dow ETF (DIA), the SPDR S&P 500 ETF (SPY), and the Invesco QQQ Trust ETF (QQQ). Additionally, I have a long position on the Energy Select Sector SPDR ETF (NYSE:XLE) and the Health Care Select Sector SPDR ETF (NYSE:XLV). I regularly rebalance my portfolio of individual stocks and ETFs based on ongoing risk assessment of both the macroeconomic environment and companies' financials. The views discussed in this article are solely the opinion of the author and should not be taken as investment advice.

1 Stock to Buy, 1 Stock to Sell This Week: Lululemon, Pfizer
 

Related Articles

1 Stock to Buy, 1 Stock to Sell This Week: Lululemon, Pfizer

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (7)
Nate Clute
RobinHoodJr Dec 18, 2023 2:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This article has aged nicely... a credit to the quality workmanship of the author
Daniel Poulin
Daniel Poulin Oct 16, 2023 10:31AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Bad news about covid sale from pfe are ending and  the short position will cover  your comment is too late.All new drug to cum on the market will up the stock after this bottom.
Ed Georges
Ed Georges Oct 16, 2023 6:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I would never Buy Lulu at Hermes or LVMH valuation. The bubble will burst very soon.
Rich Nielubowski
Rich Nielubowski Oct 15, 2023 8:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Pfizer needs an activist investor to shake up this company.
Mikko Murto
Mikko Murto Oct 15, 2023 12:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Oh well. As you are writing this article Lululemon is priced up already in the aftermarket and Pfizer lowered. Pfizer is only down because of COVID vaccines that gave it the boost to go over 60 dollars. I'm buying after tomorrows drop. They have super strong portfolio and promising future cashflows. Also P/E is around 8 now and Lululemon is way over 40. And Pfizer has some 45 billion cash in hand. Ready to buy smaller ones and powerful enough to give 5.11% dividend to investors in the future too.
Egbu Victor
Egbu Victor Oct 15, 2023 9:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thank you very much. But you mentioned that third quarter earnings season shifts into high gear for Tesla, you would have explain more about it, because from my own point of view. TSLA seems to be downward (bearish) this season.
Joma Silva
Joma Silva Oct 15, 2023 6:26AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
interesting!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email